Study S001281

An Open, Single Ascending Dose, Phase 1 Study to Assess the Pharmacokinetics, Safety, and Tolerability of NEX-22A, a Subcutaneous Prolonged-release Injection, in Male and Female Participants With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT06439056
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 12
Start: 2024-05-27
Primary completion: 2025-07-18
Lead sponsor: Nanexa AB
Conditions: Type 2 Diabetes
Interventions: DRUG:NEX-22A, a prolonged release formulation of liraglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

To evaluate the PK profile of liraglutide after single ascending doses of NEX-22A in subjects with stable type 2 diabetes [From administration of study drug until 36 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.